Physician profile
Katherine Frachetti
NPI 1508028531
$68,881.90
in general payments reported to CMS, 2019-2025
39 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,890 · 2020: $4,043 · 2021: $4,357 · 2022: $9,566 · 2023: $12K · 2024: $9,374 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $3,730 · Travel and Lodging: $32.36 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,231.25 |
| Food and Beverage | $3,730.46 |
| Travel and Lodging | $32.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,796.36 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $19,477.21 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $17,187.05 | 2019-2025 | |
| Novo Nordisk INC | $1,322.19 | 2019-2025 | Wegovy, Ozempic, Sogroya |
| Tandem Diabetes Care, INC. | $1,263.97 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $839.07 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $333.54 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $330.33 | 2019-2023 | |
| Mannkind Corporation | $274.92 | 2020-2025 | |
| Amgen INC. | $261.08 | 2019-2025 | Tepezza, Repatha, Evenity |
| Medtronic, INC. | $250.97 | 2021-2024 | Minimed 780g |
| Sequel Med Tech, LLC | $234.86 | 2025 | Twiist |
| Dexcom, INC. | $215.21 | 2019-2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $175.73 | 2020-2025 | Isturisa, Signifor Lar |
| Janssen Pharmaceuticals, INC | $172.18 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $172.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.16 | 2019-2025 | Farxiga |
| Beta Bionics, INC. | $153.30 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $136.31 | 2019-2025 | Unithroid |
| Abbott Laboratories | $133.37 | 2020-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $125.62 | 2020-2025 | Licart, Tirosint, Flector |
| Pfizer INC. | $121.19 | 2019-2022 | |
| Amarin Pharma, INC. | $97.90 | 2020-2022 | |
| Radius Health, INC. | $72.52 | 2022-2024 | Tymlos |
| Corcept Therapeutics | $57.13 | 2021-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $54.05 | 2024-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $53.31 | 2020-2022 | |
| Horizon Therapeutics Plc | $52.02 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $50.95 | 2021 | |
| Senseonics, Incorporated | $49.00 | 2019 | |
| Eusa Pharma (US) LLC | $43.55 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $42.59 | 2025 | |
| Ascensia Diabetes Care US INC. | $32.42 | 2023 | |
| Shire North American Group INC | $29.53 | 2019 | |
| Becton, Dickinson and Company | $29.07 | 2021 | |
| Almatica Pharma LLC | $24.06 | 2025 | Teriparatide |
| Zealand Pharma US, INC. | $23.27 | 2022 | |
| Cequr Corporation | $21.41 | 2023-2025 | Cequr Simplicity |
| Clarus Therapeutics INC. | $8.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Frachetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.